Checkpoint Therapeutics achieved a major milestone with the FDA approval of UNLOXCYTTM (cosibelimab-ipdl) in December 2024. This approval marks the first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC). Additionally, the company has entered into a merger agreement with Sun Pharmaceutical Industries, Inc., valued at approximately $416 million, which is expected to close in the second quarter of 2025.